

Paxman publishes newsletter on the launch of its scalp cooling clinical research data website

Today, Paxman publishes the February issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that Paxman has launched a digital library website with a wealth of scalp cooling clinical research studies and data. The Scalp Cooling Study Library is a comprehensive database which unites key published clinical research studies and data, providing an independent overview of global research and practice on scalp cooling and cryotherapy for managing the often devastating side effects of chemotherapy induced hair loss and peripheral neuropathy. The website explores the latest in scalp cooling clinical data, randomized controlled trials, multi-center studies and scientific research and hosts over 60 scalp cooling and cryocompression research studies so far.

The newsletter also includes information on Paxman's new distribution agreement with a partner in Colombia, a new upcoming clinical study by Paxman and Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine in New York City to evaluate scalp cooling for chemotherapy-induced alopecia in patients of colour in the United States, as well as many new orders and installs in the US, the UK, Russia, Australia, Turkey and a French island off Madagascar.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxfeb22en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on the launch of its scalp cooling clinical research data website](#)